Dobutamine-atropine stress echocardiography in asymptomatic healthy individuals. The relativity of stress-induced hyperkinesia.
BACKGROUND
Interpretation of dobutamine-atropine stress echocardiography (DASE) is based on the assumption that the normal response to dobutamine-atropine infusion is characterized by increased systolic thickening and motion of the left ventricular (LV) walls, whereas a reduction or no change is considered indicative of coronary artery disease. The aim of this study was to quantitatively assess changes in LV dimension and wall motion patterns during DASE in a healthy population.


RESULTS
Forty-two asymptomatic voluntary subjects (22 men) with a mean age of 59 years (range, 31 to 79 years) and a likelihood of < 5% for coronary artery disease underwent DASE with digital recording of two-dimensional and M-mode echocardiography at baseline and low-dose and peak infusion rates. Mean end-diastolic and end-systolic LV diameters and areas decreased and wall thicknesses increased progressively throughout the test. Wall motion and thickening increased from baseline to low-dose infusion in nearly all subjects. However, from low-dose to peak infusion, the mean absolute wall motion and relative wall thickening decreased by 13.1% (95% CI, 2.7 to 23.5) and 21.4% (95% CI, 6.4 to 36.4) regardless of age, sex, or use of atropine. Changes in fractional shortening and absolute wall thickening varied considerably, with a decrease observed in 15 and 13 individuals (36% and 31%), respectively.


CONCLUSIONS
In healthy subjects, measures of wall motion and wall thickening increased from baseline to low-dose infusion but decreased from low-dose to peak infusion. These findings call for revision of the assumptions on which the common analysis of DASE is based.
Department of Medicine, Rigshospitalet, University of Copenhagen, Denmark.
S
S
Carstensen
S M
SM
Ali
F V
FV
Stensgaard-Hansen
J
J
Toft
S
S
Haunsø
H
H
Kelbaek
K
K
Saunamäki
D000367:Age Factors; D001285:Atropine; D018680:Cholinergic Antagonists; D003327:Coronary Disease / Q000000981:diagnostic imaging* / Q000453:epidemiology; D004280:Dobutamine; D004452:Echocardiography / Q000379:methods*; D004562:Electrocardiography; D005080:Exercise Test; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009200:Myocardial Contraction / Q000187:drug effects / Q000502:physiology; D011446:Prospective Studies; D012307:Risk Factors; D012494:Sampling Studies; D012737:Sex Factors; D013566:Sympathomimetics; D016277:Ventricular Function, Left / Q000187:drug effects / Q000502:physiology*
D018680:Cholinergic Antagonists; D013566:Sympathomimetics; D004280:Dobutamine; D001285:Atropine